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Abstract
Due to extensive bioprospecting efforts of the past and technology factors, there have been questions about drug
discovery prospect from untapped species. We analyzed recent trends of approved drugs derived from previously untapped
species, which show no sign of untapped drug-productive species being near extinction and suggest high probability of
deriving new drugs from new species in existing drug-productive species families and clusters. Case histories of recently
approved drugs reveal useful strategies for deriving new drugs from the scaffolds and pharmacophores of the natural
product leads of these untapped species. New technologies such as cryptic gene-cluster exploration may generate novel
natural products with highly anticipated potential impact on drug discovery.
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Introduction
High-throughput screening and combinatorial chemistry based
drug discovery efforts have not led to the expected drug
productivity, raising renewed interest in searching drugs from
nature [1]_ENREF_2. Various species have been extensively
searched in the past [2–4] with few percentage of the identified
bioactive natural products carried forward to derive 939 approved
drugs [2,5] that are composed of limited number of molecular
scaffolds [6]. Natural products have fallen out of favor partly
because of technology shift [7], diminishing returns and high re-
discovery rates [8,9], and supply and screening problems [1,10].
Although new technologies are expected to overcome some of
these problems and enable significantly expanded bioprospecting
efforts [1,7,11,12], questions remain unanswered about the
prospect of deriving new drugs from untapped species at
acceptable return rates.
As part of the efforts in probing these questions, we have
recently studied the distribution patterns of nature-derived drugs
in phylogenetic trees and shown that drug-productive species tend
to be clustered in specific regions of phylogenetic space (drug-
productive clusters) with most drugs derived from existing drug-
productive families (families that have yielded at least one
approved drugs) [5]. Further clues to the prospect of deriving
drugs from untapped species and the effective drug discovery
strategies may be gained from the analysis of approved drugs
derived from previously untapped species, particularly those
approved in recent decades. In this work, we analyzed the species
origins of nature-derived drugs approved in 1991–2010 with
respect to those approved in previous decades (1961–1990) to find
the exploration trends indicative of future bioprospecting prospect
and likely sources of untapped new drug-productive species. We
also tracked development histories of several classes of approved
nature-derived drugs to reveal effective strategies for deriving new
drugs from the bioactive natural products isolated from these
species.
While the analysis of the approved drugs may provide useful
clues to the drug discovery prospect of untapped species, some
aspects of drug discovery prospect may not be fully captured
because the approved drugs are different from discovered drugs
by the additional commercial and technological considerations.
For instance, the pharmaceutical industries have moved away
from antibiotics partly because these are less lucrative than
drugs for chronic conditions [13]. The exploration of microbial
species has been limited by the cost and efficiency of cultivation
technologies, with the majority of microbial organisms remain
uncultured [14,15]. Therefore, caution needs to be exercised in
interpreting the results of our analysis, particularly with the
possibility that new technologies that explore cryptic gene-
clusters and networks [11,12,16,17], inter-species crosstalk
[11,18,19] and high-throughput fermentation [20] may provide
significantly expanded molecular scaffolds for natural product
drug discovery [15].
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Materials and Methods
A total of 939 nature-derived approved drugs have been found
from Newman and Cragg’s seminal work [2] and our own
literature search [5]. Their species origins have been identified
from comprehensive literature search by using combinations of
such keywords as drug name and alternative names, species,
natural product and nature, and the search results have been
confirmed based on such descriptions as ‘‘originates from’’,
‘‘derived from’’, ‘‘isolated from’’, or ‘‘comes from’’ a species.
The corresponding species families of the host species of these
drugs are from the NCBI taxonomy database [21]. The approval
dates of these drugs were from Newman and Cragg’s work [2] and
Drugs@FDA on FDA website (http://www.accessdata.fda.gov/
scripts/cder/drugsatfda/index.cfm).
Results and Discussion
Table 1 presents the statistics of drugs approved in every five-
year period of 1961–2010 (divided into drugs derived from
previously untapped and previous drug-productive species respec-
tively), and the statistics of drug-productive species that have
produced drugs in each period. There are 46–126 nature-derived
drugs approved in every 5-year periods since 1991, 7.1%–14.5%
of which are from previously untapped species (i.e. untapped
before the specific 5-year period) and these species represent
11.4%–41.7% of the drug-productive species that have yielded
approved drugs in 1991–2010. In contrast, there are 26–133
nature-derived drugs in every 5-year period of 1961–1990,
18.0%–62.8% of which are from previously untapped species
and these species represent 36.7%–76.2% of the drug-productive
species in 1961–1990. While the percentages have been reduced to
some extent, the recent trends of substantial percentage of drugs
and substantial percentage of drug-productive species being from
previously untapped species strongly suggests that the untapped
drug-productive species is unlikely near extinction, and future
bioprospecting efforts are expected to yield new drugs at
comparable levels. This is consistent with an earlier analysis of
the largest antibiotic-producing genus Streptomyces which suggests
that the new compound discovery rate from the unexplored strains
of Streptomyces would not decline for several decades and 15–20
antibiotics would be discovered each year at the 1995 exploration
level [9]. It is also consistent with the estimated high antibiotic
production frequencies by the untapped strains of the actinomycetes
class (561026–261021 in screening 104–107 strains) [22].
Table 2 provides the list of the new drug-productive species
emerged in 1991–2010 together with the approved drugs derived
from these species since the first drug approval. There are 59 new
drug-productive species emerged in this period, 33 (55%) of which
are from existing drug-productive species families and another 22
(37%) of which are from new species families in existing drug-
productive clusters. These suggest a high probability of finding
new drug-productive species from existing drug-productive fam-
ilies or new families located in existing drug-productive clusters.
This coincides with the reported refocused efforts for finding new
antibiotics from new sources in the actinomycetes class and
cyanobacteria phylum [22], which cover an existing drug-productive
cluster (Actinomycetales cluster) and an existing drug-productive
family (Symploca family) respectively [5].
From the time of their first drug approval to the end of 2010, these
59 new drug-productive species have yielded 85 approved drugs, 12
(14.1%) and 14 (16.5%) of which are unmodified natural products
and biologics respectively, while the majority (69.4%) of the 59 drugs
have been derived from bioactive natural products by semi-synthetic
modification, structural mimicking or pharmacophore mapping to
overcome problems frequently encountered by bioactive natural
products such as weak potency [23], low target selectivity [24],
toxicity [25], undesired pharmacokinetic properties [26], and supply
issues [27]. Retrospective study of the case histories of several classes
of recently approved drugs reveal useful strategies for deriving new
drugs from bioactive natural products from untapped species to
overcome these frequently encountered problems.
Since the discovery of Paclitaxel [28], extensive efforts have
been directed at the search of tubulin interacting anticancer drugs
from species other than the tapped taxus species, leading to the
identification of a number of natural products from untapped
Table 1. Historic data of the numbers of nature-derived approved drugs from previously untapped and previous drug-productive
species, and the numbers of drug-productive species during every five-year period from 1961 to 2010.



















1961–1965 37 22 (59.5%) 15 (40.5%) 42 32 (76.2%) 10 (23.8%)
1966–1970 26 10 (38.5%) 16 (61.5%) 26 10 (38.5%) 16 (61.5%)
1971–1975 36 8 (22.2%) 28 (77.8%) 30 11 (36.7%) 19 (63.3%)
1976–1980 78 49 (62.8%) 29 (37.2%) 80 56 (70.0%) 24 (30.0%)
1981–1985 108 30 (27.8%) 78 (72.2%) 68 31 (45.6%) 37 (54.4%)
1986–1990 133 24 (18.0%) 109 (82.0%) 63 30 (47.6%) 33 (52.4%)
1991–1995 117 17 (14.5%) 100 (85.5%) 60 25 (41.7%) 35 (58.3%)
1996–2000 126 9 (7.1%) 117 (92.9%) 58 10 (17.2%) 48 (82.8%)
2001–2005 124 12 (9.7%) 112 (90.3%) 70 19 (27.1%) 51 (72.9%)
2006–2011 46 5 (10.9%) 41 (89.1%) 44 5 (11.4%) 39 (88.6%)
doi:10.1371/journal.pone.0039782.t001
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Table 2. List of the new drug-productive species emerged in 1991–2010 together with the list of approved drugs derived from







Approved Drugs Derived from the Species






Exploration Status of Species
Family at the Time of First Drug
Approval
Period of 2001–2010
Halichondria okadai (2010) Eribulin (2010, Tubulin, anticancer, ND) Halichondriidae (2010) Newly emerged drug productive family
inside existing drug productive cluster
Isaria sinclairii (2010) Fingolimod (2010, Sphingosine-1-phosphate receptor S1PR1,
immunosuppression, ND)
Cordycipitaceae (2010) Newly emerged drug productive family
inside existing drug productive cluster
Emericella rugulosa (2007) Anidulafungin (2007, (1-.3)beta-D-glucan synthase,
antifungal, ND)
Trichocomaceae (1942) Existing drug productive family
Sorangium cellulosum (2007) Ixabepilone (2007, Tubulin, anticancer, ND) Polyangiaceae (2007) Newly emerged drug productive family
inside existing drug productive cluster
Clitopilus scyphoides (2007) Retapamulin (2007, Bacterial ribosome,
antibacterial, ND)
Entolomataceae (2007) Newly emerged drug productive family
inside existing drug productive cluster
Ecteinascidia turbinate (2007) Trabectedin (2007, DNA, anticancer, N) Perophoridae (2007) Newly emerged drug productive family
inside existing drug productive cluster
Heloderma suspectum (2005) Exenatide (2005, GLP1R, antidiabetic, ND) Helodermatidae (2005) Newly emerged drug productive family
inside existing drug productive cluster
Aspergillus fumigates (2005) Fumagillin (2005, METAP2, antiparasitic, N) Trichocomaceae (1942) Existing drug productive family
Conus geographus (2005) Omega-conotoxin MVIIA (2005, Voltage-dependent
N-type calcium channel, chronic pain relief, N)
Conidae (2005) Newly emerged drug productive family
inside existing drug productive cluster
Conus magus (2005) Omega-conotoxin MVIIA (2005, Voltage-dependent
N-type calcium channel, chronic pain relief, N)
Conidae (2005) Newly emerged drug productive family
inside existing drug productive cluster
Streptomyces filamentosus
(2003)




Existing drug productive family
Galanthus elwesii (2002) Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Galanthus nivalis (2002) Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Galanthus woronowii (2002) Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Leucojum aestivum (2002) Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Lycoris radiate (2002) Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Lycoris squamigera (2002) Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Narcissus pseudonarcissus
(2002)
Galantamine (2002, Acetylcholinesterase, Alzheimer’s disease, N) Amaryllidaceae (1983) Existing drug productive family
Cocos nucifera (2002) Gefitinib (2002, EGFR, anticancer, S/NM), Erlotinib (2004, EGFR,
anticancer, S/NM), Sunitinib (2006, VEGFR, anticancer, S/NM),
Lapatinib (2007, EGFR and HER2, anticancer, S/NM), Pazopanib
(2009, VEGFR, anticancer, S/NM)
Arecaceae (1978) Existing drug productive family
Spinacia oleracea (2002) Gefitinib (2002, EGFR, anticancer, S/NM), Erlotinib
(2004, EGFR, anticancer, S/NM), Sunitinib (2006,
VEGFR, anticancer, S/NM), Lapatinib (2007, EGFR
and HER2, anticancer, S/NM), Pazopanib (2009,
VEGFR, anticancer, S/NM)
Amaranthaceae (2002) Newly emerged drug productive family
outside existing drug productive cluster
Zea mays (2002) Gefitinib (2002, EGFR, anticancer, S/NM), Erlotinib
(2004, EGFR, anticancer, S/NM), Sunitinib (2006,
VEGFR, anticancer, S/NM), Lapatinib (2007, EGFR
and HER2, anticancer, S/NM), Pazopanib (2009,
VEGFR, anticancer, S/NM)
Poaceae (1984) Existing drug productive family
Coleophoma empetri (2002) Micafungin (2002, Beta-(1,3)-Glucan synthase,
antifungal, ND)
Coleophoma (2002) Newly emerged drug productive family





Paenibacillaceae (1942) Existing drug productive family




Existing drug productive family
Period of 1991–2000
Plectranthus barbatus (1999) Colforsin daropate (1999, Adenylate cyclase,
cardiotonic, ND)
Lamiaceae (1978) Existing drug productive family
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Exploration Status of Species




Denileukin diftitox (1999, IL-2R, anticancer, B) Corynebacteriaceae
(1999)
Newly emerged drug productive family
inside existing drug productive cluster
Lendenfeldia chondrodes
(1998)
Miglitol (1998, Alpha-glucosidase, antidiabetic, ND), Miglustat
(2003, Glucosylceramide synthase, anti-gaucher’s disease, ND)
Thorectidae (1998) Newly emerged drug productive family
inside existing drug productive cluster
Morus alba (1998) Miglitol (1998, Alpha-glucosidase, antidiabetic, ND), Miglustat
(2003, Glucosylceramide synthase, anti-gaucher’s disease, ND)
Moraceae (1998) Newly emerged drug productive family
inside existing drug productive cluster
Streptomyces toxytricini
(1998)
Orlistat (1998, Lipase, antiobesity, ND) Streptomycetaceae
(1946)
Existing drug productive family
Citrus bergamia (1997) Hesperetin (1997, Diglyceride acyltransferase, anti-cardiovascular
disease, N)
Rutaceae (1900) Existing drug productive family
Citrus limon (1997) Hesperetin (1997, Diglyceride acyltransferase, anti-cardiovascular
disease, N)
Rutaceae (1900) Existing drug productive family
Haementeria officinalis (1997) Lepirudin (1997, Thrombin, antithrombotic, ND), Bivalirudin
(2000, Thrombin, anti-cardiovascular disease, ND), Hirulog
(2000, Thrombin, anticoagulation, ND), Desirudin (2003,
Thrombin, deep vein thrombosis, ND)
Glossiphoniidae (1997) Newly emerged drug productive family
inside existing drug productive cluster
Hirudo medicinalis (1997) Lepirudin (1997, Thrombin, antithrombotic, ND), Bivalirudin
(2000, Thrombin, anti-cardiovascular disease, ND), Hirulog
(2000, Thrombin, anticoagulation, ND), Desirudin (2003,
Thrombin, deep vein thrombosis, ND)
Hirudinidae (1997) Newly emerged drug productive family
inside existing drug productive cluster
Artemisia dracunculus (1996) Latanoprost (1996, PGF receptor, antiglaucoma, ND),
Bimatoprost (2001, PGF receptor, antiglaucoma, ND),
Travoprost (2001, PGF receptor, antiglaucoma, ND)
Asteraceae (1975) Existing drug productive family
Mus musculus (1995) Edrecolomab (1995, EpCAM, anticancer, B), Daclizumab (1997,
IL-2R, immunosuppressant, B), Palivizumab (1998, Fusion
glycoprotein, antiviral, B), Trastuzumab (1998,
HER-2, anticancer, B), Alemtuzumab (2001, CD52, anticancer,
B), Efalizumab (2003, CD11a subunit of lymphocyte function-
associated antigen 1, antipsoriatic, B), Omalizumab (2003,
Human immunoglobulin E, antiasthmatic, B), Bevacizumab
(2004, VEGF-A, anticancer, B), Natalizumab (2004, Alpha-4
integrin, anti-inflammatory, B), Tocilizumab (2005, IL-6R,
immunosuppressant, B), Nimotuzumab (2006, EGFR, anticancer,
B), Ranibizumab (2006, VEGF-A, anti-angiogenic, B)
Muridae (1994) Newly emerged drug productive family
inside existing drug productive cluster
Aspergillus unilateralis (1995) Mycophenolate mofetil (1995, IMPDH2, immunosuppressant,
ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N)
Trichocomaceae (1942) Existing drug productive family
Byssochlamys nivea (1995) Mycophenolate mofetil (1995, IMPDH2, immunosuppressant,
ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N)
Trichocomaceae (1942) Existing drug productive family
Penicillium bialowiezense
(1995)
Mycophenolate mofetil (1995, IMPDH2, immunosuppressant,
ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N)
Trichocomaceae (1942) Existing drug productive family
Penicillium carneum (1995) Mycophenolate mofetil (1995, IMPDH2, immunosuppressant,
ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N)
Trichocomaceae (1942) Existing drug productive family
Penicillium fagi (1995) Mycophenolate mofetil (1995, IMPDH2, immunosuppressant, ND),
Mycophenolic acid (2003, IMPDH2, immunosuppressant, N)
Trichocomaceae (1942) Existing drug productive family
Penicillium roqueforti (1995) Mycophenolate mofetil (1995, IMPDH2, immunosuppressant,
ND), Mycophenolic acid (2003, IMPDH2, immunosuppressant, N)
Trichocomaceae (1942) Existing drug productive family
Streptomyces argenteolus
subsp. Toyonakensis (1995)
Saquinavir mesylate (1995, HIV-1 protease, anti-virus, S*/NM),
Indinavir sulfate (1996, HIV-1 protease, anti-virus, S*/NM),
Ritonavir (1996, HIV-1 protease, anti-virus, S*/NM), Neflinavir
mesylate (1997, HIV-1 protease, anti-virus, S*/NM), Amprenavir
(1999, HIV-1 protease, anti-virus, S*/NM), Lopinavir (2000,
HIV-1 protease, anti-virus, S*/NM)
Streptomycetaceae
(1946)
Existing drug productive family
Streptomyces testaceus
(1995)
Saquinavir mesylate (1995, HIV-1 protease, anti-virus, S*/NM),
Indinavir sulfate (1996, HIV-1 protease, anti-virus, S*/NM),
Ritonavir (1996, HIV-1 protease, anti-virus, S*/NM), Neflinavir
mesylate (1997, HIV-1 protease, anti-virus, S*/NM), Amprenavir
(1999, HIV-1 protease, anti-virus, S*/NM), Lopinavir (2000,
HIV-1 protease, anti-virus, S*/NM)
Streptomycetaceae
(1946)
Existing drug productive family
Camptotheca acuminate
(1994)
Irinotecan (1994, DNA topoisomerase I, anticancer, ND), Topotecan
(1996, DNA topoisomerase I, anticancer, ND)
Cornaceae (1994) Newly emerged drug productive family
outside existing drug productive cluster
Drug Discovery Prospect from Untapped Species
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species [26,27]. Two compounds, homohalichondrin B and
halichondrin B, from previously untapped western Pacific sponge
Halichondria and Axinella have shown strong cytotoxic and tubulin
polymerization inhibitory activities, but faced with supply prob-
lems [27], Subsequent works in deriving simplified and synthet-
ically accessible agents based on the halichondrin B skeleton have
led to the discovery of eribulin approved in 2009 [27] (Figure 1).







Approved Drugs Derived from the Species






Exploration Status of Species
Family at the Time of First Drug
Approval
Mappia foetida (1994) Irinotecan (1994, DNA topoisomerase I, anticancer, ND),
Topotecan (1996, DNA topoisomerase I, anticancer, ND),
Belotecan (2004, DNA topoisomerase I, anticancer, ND),
Sphingosomal topotecan (2007, DNA topoisomerase I,
anticancer, ND)
Icacinaceae (1994) Newly emerged drug productive family
inside existing drug productive cluster
Ophiorrhiza pumila (1994) Irinotecan (1994, DNA topoisomerase I, anticancer, ND),
Topotecan (1996, DNA topoisomerase I, anticancer, ND),
Belotecan (2004, DNA topoisomerase I, anticancer, ND),
Sphingosomal topotecan (2007, DNA topoisomerase I,
anticancer, ND)
Rubiaceae (1940) Existing drug productive family
Rattus norvegicus (1994) Losartan potassium (1994, AGTR1, antihypertensive, S/NM),
Valsartan (1996, AGTR1, antihypertensive, S/NM), Candesartan
cilexetil (1997, AGTR2, antihypertensive, S/NM), Eprosartan
(1997, AGTR1, antihypertensive, S/NM), Irbesartan (1997,
AGTR1, antihypertensive, S/NM), Telmisartan (1999, AGTR1,
antihypertensive, S/NM), Olmesartan medoxil (2002,
Angiotensin II receptor 1, antihypertensive, S/NM)
Muridae (1994) Newly emerged drug productive family
inside existing drug productive cluster
Erwinia chrysanthemi (1994) Pegaspargase (1994, L-asparaginase, anticancer, B) Enterobacteriaceae
(1969)
Existing drug productive family
Streptomyces hygroscopicus
(1994)
Voglibose (1994, Alpha-glucosidase, antidiabetic, N), Zotarolimus
(1996, mTOR, anticancer, ND), Sirolimus (1999, mTOR,
immunosuppressive, N), Pimecrolimus (2001, Calcineurin,
immunomodulating, ND), Vorinostat (2006, HDAC, anticancer,
ND), Temsirolimus (2007, mTOR, anticancer, ND), Everolimus
(2009, mTOR, anticancer, ND)
Streptomycetaceae
(1946)
Existing drug productive family
Corylus avellana (1993) Paclitaxel (1993, Tubulin, anticancer, N), Cabazitaxel (2010,
Tubulin, anticancer, ND)
Betulaceae (1993) Newly emerged drug productive family
inside existing drug productive cluster
Seimatoantlerium tepuiense
(1993)




Newly emerged drug productive family
outside existing drug productive cluster
Taxus baccata (1993) Paclitaxel (1993, Tubulin, anticancer, N), Docetaxel (1995, Tubulin,
anticancer, ND), Cabazitaxel (2010, Tubulin, anticancer, ND)
Taxaceae (1993) Newly emerged drug productive family
inside existing drug productive cluster
Taxus brevifolia (1993) Paclitaxel (1993, Tubulin, anticancer, N), Docetaxel (1995, Tubulin,
anticancer, ND), Cabazitaxel (2010, Tubulin, anticancer, ND)
Taxaceae (1993) Newly emerged drug productive family
inside existing drug productive cluster
Taxus wallichiana (1993) Paclitaxel (1993, Tubulin, anticancer, N), Docetaxel (1995, Tubulin,
anticancer, ND), Cabazitaxel (2010, Tubulin, anticancer, ND)
Taxaceae (1993) Newly emerged drug productive family
inside existing drug productive cluster
Streptomyces tsukubaensis
(1993)
Tacrolimus (1993, Calcineurin, immunosuppressant, N) Streptomycetaceae
(1946)
Existing drug productive family
Larrea tridentate (1992) Masoprocol (1992, 5-LOX, anticancer, N) Zygophyllaceae (1978) Existing drug productive family
Agaricus bisporus (1991) Calcipotriol (1991, Vitamin D receptor, antipsoriatic, ND),
Tacalcitol (1993, Vitamin D receptor, antipsoriatic, ND),
Paricalcitol (1998, Vitamin D receptor, calcium metabolism,
ND), Doxercalciferol (1999, Vitamin D receptor, calcium
metabolism, ND)
Agaricaceae (1991) Newly emerged drug productive family
inside existing drug productive cluster
Leontice leontopetalum (1991) Doxacurium chloride (1991, CHRNA2, muscle relaxant, S*),
Mivacurium chloride (1992, CHRNA2, muscle relaxant, S*),
Cisatracurium besilate (1995, nAChR, muscle relaxant, S*)
Berberidaceae (1978) Existing drug productive family
Callistemon citrinus (1991) Nitisinone (1991, 4HPPD, antityrosinaemia, ND) Myrtaceae (1991) Newly emerged drug productive family
inside existing drug productive cluster
The categories of drug source are based on the definition of Newman and Cragg [2]: ‘‘B’’ Biological; usually a large (.45 residues) peptide or protein either isolated from
an organism/cell line or produced by biotechnological means in a surrogate host,‘‘N’’ Natural product, ‘‘ND’’ Derived from a natural product and is usually a
semisynthetic modification, ‘‘S*’’ Made by total synthesis, but the pharmacophore is/was from a natural product.‘‘V’’ Vaccine, ‘‘NM’’ Natural product mimic.
doi:10.1371/journal.pone.0039782.t002
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particularly epothilone B, from the previously untapped myxo-
bacterium Sorangium cellulosum species as tubulin interacting
anticancer agents with potent cytotoxic activity toward paclitaxel-
sensitive and paclitaxel-resistant cells [26]. But these compounds
are prone to the inactivation by esterase cleavage, and in an effort
of overcoming this problem semisynthetic lactam analogs of
epothilone B has been derived which led to the discovery of
Ixabepilone approved in 2009 [26] (Figure 2).
The identification of BCR-ABL as a key target of chronic
myeloid leukemia has prompted extensive efforts in identifying
anticancer ABL inhibitor drugs [29]. Design works based on the
pharmacophore of a nonselective pan-kinase inhibitor staurospor-
ine from the previously untapped Lentzea albida species have
resulted in an EGFR selective inhibitor CGP 52411 [24] and
subsequently a potent ABL selective inhibitor CGP 57148 [30].
CGP 57148 has undesired pharmacokinetic properties, which is
improved by formulating it with mesylate salt leading to Gleevec, a
milestone anticancer kinase inhibitor approved in 2001 [31]
(Figure 3).
The identification of HIV-1 protease as a key anti-HIV target
has also motivated extensive efforts in identifying HIV-protease
inhibitor drugs. Before the start of HIV-1 protease inhibitor
projects, pepstatin from previously untapped Streptomyces argenteolus
subsp. Toyonakensis and Streptomyces testaceus species has been found to
show weak human rennin inhibitory activities, and more potent
peptidomimetic human rennin inhibitors have been derived from
it by further optimizing binding configuration to better mimicking
substrate binding [23]. Based on these works, a series of potent
peptidomimetic HIV-protease inhibitors have been designed
[32,33], leading to a series of approved anti-HIV drugs
Saquinavir, Indinavir, Ritonavir, Neflinavir, Amprenavir, and
Lopinavir in 1995–2000.
In 2001–2011, some new molecular scaffolds have been derived
from both previously explored species and previously untapped
species. For instance, the 4-anilinoquinazoline scaffold in Gefiti-
Figure 1. The route of deriving eribulin (approved in 2009) from natural product halichondrin B.
doi:10.1371/journal.pone.0039782.g001
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nib, Erlotinib and Lapatinib has been derived based on the
pharmacophore of a selective kinase inhibitor olomoucine, a semi-
synthetic derivative of zeatin from Maize, Cocos nucifera, Spinacia
oleracea, and Pisum sativum species that have been previously
explored for deriving cardiovascular and anthelmintic agents [34–
36]. The 2-phenylaminopyrimidine scaffold in Imatinib and
Nilotinib has been derived based on the pharmacophore of a
nonselective pan-kinase inhibitor staurosporine from the previ-
ously untapped Lentzea albida species [24,30,31]. During the same
period of time, many of the existing molecular scaffolds (those
found in nature-derived drugs approved before the period)
continue to contribute new approved drugs. Examples are the
tetracycline scaffold of Minocycline, Methacycline and Tigecycline
approved in 2001 and 2005 respectively, and the steroide scaffold
of Falecalcitrol and Acetyldigitoxin approved in 2001 and 2002
respectively.
While most of the 2001–2011 approved nature-derived drugs
targeting previously-explored pathways, some previously un-
targeted pathways have become highly successfully targeted.
These are MAPK, ErbB, mTOR, Brc-Abl regulated, and
hematopoietic cell lineage pathways targeted by 7, 6, 3, 3 and 3
new drugs respectively. These pathways become successfully
targeted partly because of the derivation of selective kinase
inhibitory scaffolds based on the pharmacophores of zeatin
derivatives [34–36] and staurosporine [24,30,31] etc. Some
previously successfully explored pathways continue to be success-
fully targeted. Specifically, the calcium signaling, insulin signaling,
and Toll-like receptor pathways are targeted by 10, 4, and 6 drugs
approved before 2001 and 5, 4, and 4 drugs approved during
2001–2011 respectively.
Our analysis suggests that untapped drug-productive species are
unlikely to be near extinction, and there is a high probability for
finding new drug-productive species in the existing drug-produc-
tive families and drug-productive clusters. New technologies that
explore cryptic gene-clusters [11], pathways [12,17], inter-species
crosstalk [11,18,19] and high-throughput fermentation [20] enable
the generation of significantly more diverse groups of novel natural
products, which has been anticipated to have some impact on drug
productivity from nature. Some of the revolutionary new drugs of
novel targets, such as Gleevec and Gefitinib approved in recent
years and Saquinavir and Paclitaxel from earlier years, as well as
new drugs of existing targets, have been derived from bioactive
natural products of previously untapped species. Retrospective
analysis of the case histories of these drugs reveals useful strategies
for deriving new drugs from these natural sources.
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Figure 2. The route of deriving Ixabepilone (approved in 2009) from natural product epothilone B.
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